Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study.

AI NSCLC Prediction Therapy

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
23 Aug 2024
Historique:
received: 12 03 2024
revised: 05 07 2024
accepted: 11 08 2024
medline: 15 9 2024
pubmed: 15 9 2024
entrez: 14 9 2024
Statut: aheadofprint

Résumé

Molecular profiling of lung cancer is essential to identify genetic alterations that predict response to targeted therapy. While deep learning shows promise for predicting oncogenic mutations from whole tissue images, existing studies often face challenges such as limited sample sizes, a focus on earlier stage patients, and insufficient analysis of robustness and generalizability. This retrospective study evaluates factors influencing mutation prediction accuracy using the large Heidelberg Lung Adenocarcinoma Cohort (HLCC), a cohort of 2356 late-stage FFPE samples. Validation is performed in the publicly available TCGA-LUAD cohort. Models trained on the larger HLCC cohort generalized well to the TCGA dataset for mutations in EGFR (AUC 0.76), STK11 (AUC 0.71) and TP53 (AUC 0.75), in line with the hypothesis that larger cohort sizes improve model robustness. Variation in performance due to pre-processing and modeling choices, such as mutation variant calling, affected EGFR prediction accuracy by up to 7 %. Model explanations suggest that acinar and papillary growth patterns are critical for the detection of EGFR mutations, whereas solid growth patterns and large nuclei are indicative of TP53 mutations. These findings highlight the importance of specific morphological features in mutation detection and the potential of deep learning models to improve mutation prediction accuracy. Although deep learning models trained on larger cohorts show improved robustness and generalizability in predicting oncogenic mutations, they cannot replace comprehensive molecular profiling. However, they may support patient pre-selection for clinical trials and deepen the insight in genotype-phenotype relationships.

Identifiants

pubmed: 39276594
pii: S0959-8049(24)00948-1
doi: 10.1016/j.ejca.2024.114292
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114292

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Gabriel Dernbach (G)

Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany; BIFOLD, Berlin, Germany; Aignostics GmbH, Berlin, Germany.

Daniel Kazdal (D)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69120 Heidelberg, Germany.

Lukas Ruff (L)

Aignostics GmbH, Berlin, Germany.

Maximilian Alber (M)

Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany; Aignostics GmbH, Berlin, Germany.

Eva Romanovsky (E)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Simon Schallenberg (S)

Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany.

Petros Christopoulos (P)

Department of Thoracic Oncology, Thoraxklinik and National Centre for Tumour Diseases (NCT) at Heidelberg University Hospital, 69126 Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69120 Heidelberg, Germany.

Cleo-Aron Weis (CA)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Thomas Muley (T)

Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, 69126 Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69120 Heidelberg, Germany.

Marc A Schneider (MA)

Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, 69126 Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69120 Heidelberg, Germany.

Peter Schirmacher (P)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Michael Thomas (M)

Department of Thoracic Oncology, Thoraxklinik and National Centre for Tumour Diseases (NCT) at Heidelberg University Hospital, 69126 Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69120 Heidelberg, Germany.

Klaus-Robert Müller (KR)

BIFOLD, Berlin, Germany; Machine Learning Group, Technical University of Berlin, Marchstr. 23, 10587 Berlin, Germany; Department of Artificial Intelligence, Korea University, Seoul 136-713, South Korea; Max-Planck-Institute for Informatics, Stuhlsatzenhausweg 4, 66123 Saarbrücken, Germany.

Jan Budczies (J)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center (DKTK/DKFZ), Heidelberg, Germany.

Albrecht Stenzinger (A)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center (DKTK/DKFZ), Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69120 Heidelberg, Germany. Electronic address: Albrecht.stenzinger@med.uni-heidelberg.de.

Frederick Klauschen (F)

Institute of Pathology, Charité Universitätsmedizin, Berlin, Germany; BIFOLD, Berlin, Germany; German Cancer Consortium, German Cancer Research Center (DKTK/DKFZ), Munich Partner Site, Germany; Institute of Pathology, LMU München, München, Germany. Electronic address: Frederick.klauschen@med.uni-muenchen.de.

Classifications MeSH